Company Profile

Amgen Inc (AKA: Applied Molecular Genetics Inc)
Profile last edited on: 10/31/2022      CAGE: 0JVZ6      UEI: D92HARF1LKA9

Business Identifier: Therapeutic products in supportive of cancer care, inflammation, nephrology and bone disease
Year Founded
1980
First Award
1986
Latest Award
1989
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

One Amgen Center Drive
Thousand Oaks, CA 91320
   (805) 447-1000
   dkaye@amgen.com
   www.amgen.com
Location: Multiple
Congr. District: 26
County: Ventura

Public Profile

Originally formed as Applied Molecular Genetics Inc, Amgen is now the largest of the biotechs, Amgen makes and markets therapeutic products for hematopoiesis (blood cell production), inflammation and autoimmunity, neurobiology, and soft-tissue repair. Already Publicy traded (1983), before their first SBIR award in 1986, Amgen's SBIR participation was limited and very early in the firms development - but nonetheless an important part of the start-up effort. The Corporation's key products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company's principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company's products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. It is useful also to note that of the NINE acquisitions so far, FIVE have been themselves SBIR involved.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
500+
Revenue Range
Over 50M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
NASDAQ : AMGN
IP Holdings
500+

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1989 2 NIH $650,000
Project Title: Recombinate DNA derived pertussis subunit vaccine
1989 1 NIH $50,000
Project Title: Expression of Synthetic DNA Sequences Encoding the HTLV-1 Envelope in E coli

Key People / Management

  Kevin W Sharer -- President

  Walter Neal Burnette

  David L Hare